Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Lyell Immunopharma (LYEL) over the last 5 years, with Q3 2025 value amounting to 0.94%.

  • Lyell Immunopharma's Return on Capital Employed fell 5800.0% to 0.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.94%, marking a year-over-year decrease of 5800.0%. This contributed to the annual value of 0.63% for FY2024, which is 3300.0% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Return on Capital Employed is 0.94%, which was down 5800.0% from 0.96% recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Return on Capital Employed peaked at 0.18% during Q3 2021, and registered a low of 0.96% during Q2 2025.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.26% (2023), whereas its average is 0.4%.
  • As far as peak fluctuations go, Lyell Immunopharma's Return on Capital Employed surged by 100bps in 2023, and later plummeted by -6100bps in 2025.
  • Over the past 5 years, Lyell Immunopharma's Return on Capital Employed (Quarter) stood at 0.19% in 2021, then fell by -6bps to 0.2% in 2022, then crashed by -65bps to 0.33% in 2023, then crashed by -114bps to 0.72% in 2024, then plummeted by -31bps to 0.94% in 2025.
  • Its last three reported values are 0.94% in Q3 2025, 0.96% for Q2 2025, and 0.86% during Q1 2025.